Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

181. Walking prescription of 10 000 steps per day in patients with type 2 diabetes mellitus: a randomised trial in Nigerian general practice

Walking prescription of 10 000 steps per day in patients with type 2 diabetes mellitus: a randomised trial in Nigerian general practice 29335328 2018 02 01 1478-5242 68 667 2018 Feb The British journal of general practice : the journal of the Royal College of General Practitioners Br J Gen Pract Walking prescription of 10 000 steps per day in patients with type 2 diabetes mellitus: a randomised trial in Nigerian general practice. e139-e145 10.3399/bjgp18X694613 In clinical practice, translating (...) the benefits of a sustained physically active lifestyle on glycaemic control in patients with type 2 diabetes mellitus (T2DM) is difficult. A walking prescription may be an effective alternative. To examine the effect of a 10 000 steps per day prescription on glycaemic control of patients with T2DM. Forty-six adults with T2DM attending a general outpatient clinic were randomised into two equal groups. The intervention group was given goals to accumulate 10 000 steps per day for 10 weeks, whereas

EvidenceUpdates2018

182. Weight-based carbohydrate treatment of hypoglycaemia in people with Type 1 diabetes using insulin pump therapy: a randomized crossover clinical trial

Weight-based carbohydrate treatment of hypoglycaemia in people with Type 1 diabetes using insulin pump therapy: a randomized crossover clinical trial 29285796 2018 02 13 1464-5491 35 3 2018 Mar Diabetic medicine : a journal of the British Diabetic Association Diabet. Med. Weight-based carbohydrate treatment of hypoglycaemia in people with Type 1 diabetes using insulin pump therapy: a randomized crossover clinical trial. 339-346 10.1111/dme.13576 To test whether weight-based treatment is more (...) effective than usual care in people with Type 1 diabetes receiving continuous subcutaneous insulin infusion therapy with regard to both hypoglycaemia and avoiding excessive rebound hyperglycaemia. Children and adults on continuous subcutaneous insulin infusion were enrolled into a study with a crossover design. Each episode of hypoglycaemia (defined as capillary glucose <4.0 mmol/l) was randomly assigned one of two treatment protocols using glucose tablets: either 0.3 g/kg body weight or usual treatment

EvidenceUpdates2018

183. Disordered Eating Behaviors Are Not Increased by an Intervention to Improve Diet Quality but Are Associated With Poorer Glycemic Control Among Youth With Type 1 Diabetes

Disordered Eating Behaviors Are Not Increased by an Intervention to Improve Diet Quality but Are Associated With Poorer Glycemic Control Among Youth With Type 1 Diabetes 29371234 2018 01 26 1935-5548 2018 Jan 25 Diabetes care Diabetes Care Disordered Eating Behaviors Are Not Increased by an Intervention to Improve Diet Quality but Are Associated With Poorer Glycemic Control Among Youth With Type 1 Diabetes. dc170090 10.2337/dc17-0090 This study examines whether participation in an 18-month (...) behavioral intervention shown previously to improve overall diet quality inadvertently increases disordered eating behaviors (DEBs) in youth with type 1 diabetes and investigates the association of DEB with multiple measures of glycemic control and variability. Participants reported DEB and diabetes management at baseline and 6, 12, and 18 months; masked continuous glucose monitoring (CGM), HbA 1c , and 1,5-anhydroglucitol were obtained concurrently. Linear mixed models estimated the intervention effect

EvidenceUpdates2018

184. Continuous Monitoring of Glucose for Type 1 Diabetes

of patients with type 1 diabetes and parents of children with type 1 diabetes, who described the social, clinical, and safety benefits of continuous glucose monitoring. Based on these considerations, Health Quality Ontario decided to recommend public funding for continuous glucose monitoring for patients who meet certain criteria. Continuous Monitoring of Glucose for Type 1 Diabetes. February 2018; pp. 1–3 2 Decision Determinants for Continuous Monitoring of Glucose for Type 1 Diabetes Decision Criteria (...) technology/intervention? Based on a 2% current use of continuous glucose monitors (n = 2,091) and approximately 20% increase in uptake per year above the current usage, publicly funding continuous glucose monitoring for people with type 1 diabetes may result in extra spending, ranging from $8.5 million to $16.2 million per year over the next 5 years. Publicly funding continuous glucose monitoring in a larger population (e.g., all patients with type 1 diabetes who have hypoglycemia unawareness) would

Health Quality Ontario2018

185. Bariatric surgery for Type 2 Diabetes and a body mass index below 35

Bariatric surgery for Type 2 Diabetes and a body mass index below 35 Bariatric surgery for Type 2 Diabetes and a body mass index below 35 - Health Technology Assessment - NIPH Selected items added to basket Close Vis søkefelt How can we help you today? Search for: Søk Menu • Bariatric surgery for Type 2 Diabetes and a body mass index below 35 - Health Technology Assessment Søk i Folkehelsa.no Search for: Søk Infectious diseases & Vaccines Close Mental & Physical health Close Environment (...) & Lifestyle Close Health in Norway Close Quality & Knowledge Close Research & Access to data Close We have conducted a health technology assessment (HTA) that addresses efficacy, safety and a health-economic evaluation of bariatric surgery for patients with type 2 diabetes and a BMI below 35 compared to standard treatment. We included four randomized and six non-randomized controlled studies as well as one large registry study with no control group. After two-years of follow-up we found that: On average

Norwegian Institute of Public Health2018

186. Ertugliflozin - Steglatro, Steglujan (ertugliflozin and sitagliptin), Segluromet (ertugliflozin and metformin hydrochloride) - Type 2 diabetes

Ertugliflozin - Steglatro, Steglujan (ertugliflozin and sitagliptin), Segluromet (ertugliflozin and metformin hydrochloride) - Type 2 diabetes Steglatro (ertugliflozin), Steglujan (ertugliflozin and sitagliptin), Segluromet (ertugliflozin and metformin hydrochloride) Tablets U.S. Department of Health and Human Services Search FDA Submit search Steglatro (ertugliflozin), Steglujan (ertugliflozin and sitagliptin), Segluromet (ertugliflozin and metformin hydrochloride) Tablets Steglatro Company

FDA - Drug Approval Package2018

187. Vitamin D Supplementation in Patients With Type 2 Diabetes: The Vitamin D for Established Type 2 Diabetes (DDM2) Study

Vitamin D Supplementation in Patients With Type 2 Diabetes: The Vitamin D for Established Type 2 Diabetes (DDM2) Study 29577107 2018 11 14 2472-1972 2 4 2018 Apr 01 Journal of the Endocrine Society J Endocr Soc Vitamin D Supplementation in Patients With Type 2 Diabetes: The Vitamin D for Established Type 2 Diabetes (DDM2) Study. 310-321 10.1210/js.2018-00015 Observational data support a role for vitamin D in type 2 diabetes, but evidence from trials is inconclusive. To evaluate the effect (...) of vitamin D supplementation on β -cell function and hemoglobin A1c (HbA1c) in patients with well-controlled type 2 diabetes. Double-blind, randomized, placebo-controlled clinical trial. Tufts Medical Center, Boston, MA; VA Medical Center, Cincinnati, OH. A total of 127 patients (mean age, 60 years) with stable (HbA1c ≤7.5%) diabetes managed with lifestyle only or lifestyle plus metformin. Subjects were given 4000 units of vitamin D 3 (cholecalciferol) daily or placebo for 48 weeks. Insulin secretion

Journal of the Endocrine Society2018 Full Text: Link to full Text with Trip Pro

188. Factors associated with depression in patients with type 2 diabetes in the Gaza Strip: a cross sectional study.

Factors associated with depression in patients with type 2 diabetes in the Gaza Strip: a cross sectional study. BACKGROUND: About 9% of the world's population has diabetes. Most people with diabetes live in developing countries. Diabetes is the fourth leading cause of death in the occupied Palestinian territory. The likelihood of diabetes complications increases with depression. Worldwide, about half of patients with diabetes have severe depression that has been misidentified by health (...) providers. The aim of this study was to examine factors associated with depression in patients with type 2 diabetes in the Gaza governorate. METHODS: This cross-sectional study included patients attending three primary health centres in 2016. A convenient purposive approach to sampling was used to select three centres from the 15 centres in the Gaza governorate, covering the east (border), middle, and west areas. Since 2014, all patients with type 2 diabetes have been screened for depression using

Lancet2018

189. The effectiveness of counselling interventions in reducing HbA<sub>1c</sub> concentrations in patients with type 2 diabetes: a modelling study.

The effectiveness of counselling interventions in reducing HbA1c concentrations in patients with type 2 diabetes: a modelling study. BACKGROUND: The burden of type 2 diabetes is increasing rapidly in the occupied Palestinian territory. Different counselling interventions have been applied worldwide to reduce HbA 1c concentrations in patients with type 2 diabetes. Achieving good glycaemic control is important for prevention of complications of type 2 diabetes. The aim (...) of this modelling study was to assess the effectiveness of different counselling interventions in improving glycaemic control in patients with type 2 diabetes. METHODS: The scientific literature was reviewed to identify relevant interventions that can reduce HbA 1c concentrations in patients with type 2 diabetes. We included articles describing interventions tested at the primary health-care level and targeting patients with type 2 diabetes. Based on WHO's "Best Buys", and taking into consideration

Lancet2018

190. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.

Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. BACKGROUND: The effectiveness of real-time continuous glucose monitoring (rtCGM) in avoidance of hypoglycaemia among high-risk individuals with type 1 diabetes treated with multiple daily insulin injections (MDI) is unknown. We aimed to ascertain whether (...) the incidence and severity of hypoglycaemia can be reduced through use of rtCGM in these individuals. METHODS: The HypoDE study was a 6-month, multicentre, open-label, parallel, randomised controlled trial done at 12 diabetes practices in Germany. Eligible participants had type 1 diabetes and a history of impaired hypoglycaemia awareness or severe hypoglycaemia during the previous year. All participants wore a masked rtCGM system for 28 days and were then randomly assigned to 26 weeks of unmasked rtCGM

Lancet2018

191. Investigating the Early Life Determinants of Type-II Diabetes Using a Project Talent-Medicare Linked Data-set

Investigating the Early Life Determinants of Type-II Diabetes Using a Project Talent-Medicare Linked Data-set Redirecting

SSM - population health2018 Full Text: Link to full Text with Trip Pro

192. CISH promoter polymorphism effects on T cell cytokine receptor signaling and type 1 diabetes susceptibility

a central role in the development of type 1 diabetes (T1D). Interleukin-2 receptor (IL-2R) signaling is essential for regulatory T cells (T REG ), and cytokine-inducible SH2-containing protein (CIS) regulates IL-2R signaling as a feedback inhibitor. Previous studies identified association of CISH promoter region single nucleotide polymorphisms (SNPs) with susceptibility to infectious diseases. Methods: Here we analyzed allele frequencies of three CISH SNPs (i.e., rs809451, rs414171, rs2239751 (...) SNPs with susceptibility to T1D or severity of disease. In contrast to previous studies, no influence of different haplotypes on CIS mRNA expression or T cell-mediated functions was found. Keywords: CIS, CISH, Single nucleotide polymorphisms, IL-2, Regulatory T cells, Effector T cells Background Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by the destruction of pancreatic ß cells. Autoreactive effector T cells are involved in T1D patho- genesis, and impaired regulatory T cell

Molecular and cellular pediatrics2018 Full Text: Link to full Text with Trip Pro

193. Statement on prescribing Freestyle Libre flash glucose monitoring system for type 1 and type 2 diabetes

Statement on prescribing Freestyle Libre flash glucose monitoring system for type 1 and type 2 diabetes

Health Technology Wales2018

194. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial 29266675 2018 02 07 1463-1326 2017 Dec 21 Diabetes, obesity & metabolism Diabetes Obes Metab Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. 10.1111/dom (...) .13194 To evaluate the efficacy and safety of ertugliflozin and sitagliptin co-administration vs the individual agents in patients with type 2 diabetes who are inadequately controlled with metformin. In this study (Clinicaltrials.gov NCT02099110), patients with glycated haemoglobin (HbA1c) ≥7.5% and ≤11.0% (≥58 and ≤97 mmol/mol) with metformin ≥1500 mg/d (n = 1233) were randomized to ertugliflozin 5 (E5) or 15 (E15) mg/d, sitagliptin 100 mg/d (S100) or to co-administration of E5/S100 or E15/S100

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

195. Long-term effects on glycaemic control and beta-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial

Long-term effects on glycaemic control and beta-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial 29272062 2018 01 23 1463-1326 2017 Dec 22 Diabetes, obesity & metabolism Diabetes Obes Metab Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial. 10.1111/dom.13196 To determine the effects of early (...) intensive glycaemic control with intensive insulin treatment (IIT) or initial combined oral antidiabetic drug (COAD) therapy on long-term glycaemic control and the preservation of β-cell function in people with type 2 diabetes mellitus (T2DM). Newly diagnosed drug-naïve patients with T2DM from 8 outpatient diabetes centres were randomized to receive either IIT (n = 50; glargine/glulisine) or COAD (n = 47; glimepiride/metformin) as intensive treatment until the termination criteria to ensure euglycaemia

EvidenceUpdates2018

196. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials

Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials 29205774 2018 01 09 1463-1326 2017 Dec 05 Diabetes, obesity & metabolism Diabetes Obes Metab Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials. 10.1111/dom.13185 To assess the evidence supporting the choice of third-line (...) agents in adults with inadequately controlled type 2 diabetes. We searched randomized controlled trials (RCTs) published between January 2000 and July 2017 that reported data on cardiometabolic outcomes and hypoglycaemia for glucose-lowering agents added to metformin-based dual treatments. Data were stratified by background therapy and RCT duration, and synthesized, when possible, with network meta-analyses. A total of 43 RCTs (16 590 participants) were included, with metformin combined

EvidenceUpdates2018

197. Comparative effectiveness of Roux-en-Y gastric bypass and sleeve gastrectomy for treatment of type ii diabetes: a review of reviews

Comparative effectiveness of Roux-en-Y gastric bypass and sleeve gastrectomy for treatment of type ii diabetes: a review of reviews Comparative effectiveness of Roux-en-Y gastric bypass and sleeve gastrectomy for treatment of type ii diabetes: a review of reviews Comparative effectiveness of Roux-en-Y gastric bypass and sleeve gastrectomy for treatment of type ii diabetes: a review of reviews HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Comparative effectiveness of Roux-en-Y gastric bypass and sleeve gastrectomy for treatment of type ii diabetes: a review of reviews. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions Roux-en-Y gastric bypass is a surgery that reduces the capacity of the stomach and the length of the small intestine through which food travels. Sleeve gastrectomy

Health Technology Assessment (HTA) Database.2018

198. [Saxagliptin/metformin (type 2 diabetes) - benefit assessment according to õ35a Social Code Book V]

[Saxagliptin/metformin (type 2 diabetes) - benefit assessment according to õ35a Social Code Book V] Saxagliptin/metformin (Diabetes mellitus typ 2): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17 [Saxagliptin/metformin (type 2 diabetes) - benefit assessment according to §35a Social Code Book V] Saxagliptin/metformin (Diabetes mellitus typ 2): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17 [Saxagliptin/metformin (type 2 diabetes) - benefit assessment according (...) (type 2 diabetes) - benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 554. 2017 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Humans; Metformin; saxagliptin Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8

Health Technology Assessment (HTA) Database.2018

199. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease 28904068 2018 02 07 1524-4539 137 2 2018 Jan 09 Circulation Circulation Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. 119-129 10.1161/CIRCULATIONAHA.117.028268 Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced cardiovascular morbidity (...) and mortality in patients with type 2 diabetes mellitus and established cardiovascular disease in the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients). Urinary glucose excretion with empagliflozin decreases with declining renal function, resulting in less potency for glucose lowering in patients with kidney disease. We investigated the effects of empagliflozin on clinical outcomes in patients with type 2 diabetes mellitus, established

EvidenceUpdates2018

200. Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naive Chinese patients: Analysis of results from the CONSENT trial

Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naive Chinese patients: Analysis of results from the CONSENT trial 29227571 2018 01 23 1463-1326 2017 Dec 11 Diabetes, obesity & metabolism Diabetes Obes Metab Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients (...) : Analysis of results from the CONSENT trial. 10.1111/dom.13190 Metformin treatment for type 2 diabetes mellitus (T2DM) can be limited by gastrointestinal (GI) adverse events (AEs), resulting in treatment discontinuation. We investigated whether once-daily metformin extended release (XR) is superior in terms of GI tolerability, with non-inferior efficacy, compared with thrice-daily metformin immediate release (IR) in treatment-naïve Chinese patients with T2DM. This prospective, open-label, randomized

EvidenceUpdates2018